A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations

Inclusion Criteria: * Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form * Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination * Participants with a Fitzpatrick Skin Type of I, II or III * Participants with an Individual Typology Angle (ITA°) greater than 28° Exclusion Criteria: * Women who are known to be pregnant or who are intending to become pregnant over the duration of the study * Women who are breast-feeding or lactating * Participants having used medication with known photo-toxic and/or photosensitizing potential (e.g. hypericum perforatum, antibiotics, blood pressure regulating agents) up to 14 days prior to screening * Participants with a history of systemic therapy with anti-inflammatory agents or analgesics (e.g. diclofenac) up to 3 days prior to screening * Participants with dermatological conditions * Participants with a history of abnormal response to the sun * Participants having marks, blemishes or nevi or presenting existing sun damage in the test area * Participants having excessive hair, moles, tattoos, scars or other imperfections in the test area that could influence the investigation * Participants with a history of systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. anti-allergics) up to 7 days prior to screening * Participants with a non-uniform skin colour or hyperpigmentation in the test area * Participants with a medical history of dysplastic nevi or melanoma * Participants with one of the following illnesses that might require regular systemic medication: Insulin-dependent diabetes, cancer * Participants with asthma, unless medicated * Participants with an electronic implant (e.g. pace maker, insulin pump, hearing aid) that cannot be removed during irradiation * AIDS (acquired immune deficiency syndrome) and infectious hepatitis, if known to the participants * Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients * Known allergy to latex * Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days prior to screening * Participation in another clinical study involving UV exposure to the same test site up to 2 months prior to screening * Previous participation in this study * Recent history (within the last 5 years) of alcohol or other substance abuse * Participants who have used a tanning bed or other tanning treatment on the back area up to 1 month prior to screening * Participants accustomed to using tanning beds * Participants who have used self-tanning products on the back area in the previous 1 month prior to screening * An employee of the sponsor or the study site or members of their immediate family